By Sabela Ojea

 

GlaxoSmithKline PLC said Wednesday that its Nucala monoclonal antibody has been approved in Europe by the European Commission for three additional eosinophil-driven diseases.

The British pharma major said this antibody is the first approved targeted treatment for use in four of these eosinophil-driven conditions.

Eosinophil-driven diseases are inflammatory conditions linked to elevated levels of eosinophils, a type of white blood cell, the company said.

 

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

 

(END) Dow Jones Newswires

November 17, 2021 02:40 ET (07:40 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Glaxosmithkline (LSE:GSK)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Glaxosmithkline Charts.
Glaxosmithkline (LSE:GSK)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Glaxosmithkline Charts.